Skip to main content
. Author manuscript; available in PMC: 2010 Aug 4.
Published in final edited form as: Curr Protoc Immunol. 2007 May;CHAPTER:Unit–15.1. doi: 10.1002/0471142735.im1501s77

Table 15.1.2.

Summary of General Parameters for Various EAE Adoptive Transfer Modelsa

Mouse strain Antigen specificity Donor immunization period (days) In vitro antigen concentration (mg/ml) In vitro IL-12 (ng/ml) In vitro culture Time (hr) Number of blasts transferred (×106) Disease type Disease severity
SJL PLP 7-14 50-100 72-96 5-10 Relapsing-remitting Severe
PLP139-151 7-14 20 72-96 1-5 Relapsing-remitting Severe
MBP 7-14 50-100 72-96 40-60 Relapsing-remitting Moderate
MBP84-104 7-14 50 72-96 10-20 Relapsing-remitting Moderate
C57BL/6 MBP 10-14 50-100 72-96 50 Monophasic/chronic Mild
MBP84-104 10-14 50 72-96 50 Monophasic/chronic Mild
MOG 10-14 50 25 72-96 20 Chronic Moderate
MOG35-55 10-14 10 25 72-96 20 Chronic Moderate
B10.PLb MBPAc1-11 50 10 72 1 Monophasic Moderate
B10.S MBP 10-11 25 20 96 35 Monophasic Moderate
MBP87-106 10-11 50 20 96 35 Monophasic Moderate
a

These parameters have been optimized in different laboratories as previously described. SJL protocol parameters are from Pettinelli and McFarlin (1981), Pettinelli et al. (1982), Miller et al. (1991), McRae et al. (1992), Fritz and Zhao (1994), Segal et al. (1994), Skundric et al. (1993, 1994), and Tuohy and Thomas (1995). C57BL/6 protocol parameters are from Mendel et al. (1995), Shaw et al. (1995), Clark et al. (1997), Segal et al. (1998), Mendel and Shevach (2002), and Tompkins et al. (2002). B10.PL protocol parameters are from Walker and Mannie (2002). B10.S protocol parameters are from Segal and Shevach (1996).

b

Note that the B10.PL system employs T cell receptor transgenic donors which do not require in vivo priming, only in vitro culture with MBPAc1-11 peptide and rIL-12.

HHS Vulnerability Disclosure